Recombinant human FVIIa for reducing the need for invasive second-line therapies in severe refractory postpartum hemorrhage: A multicenter, randomized, open controlled trial

Journal of Thrombosis and Haemostasis

Volumn 13, Issue 4, 2015, Pages 520-529

  Lavigne Lissalde, G ^a,b   Aya, A G ^a   Mercier, F J ^c   Roger Christoph, S ^d   Chauleur, C ^e   Morau, E ^f   Ducloy Bouthors, A S ^g   Mignon, A ^h   Raucoules, M ⁱ   Bongain, A ⁱ   Boehlen, F ^j   de Moerloose, P ^j   Bouvet, S ^a   Fabbro Peray, P ^a   Gris, J C ^a,b  

^a DEPARTMENT OF NEUROLOGY   (France)

^b UNIV MONTPELLIER   (France)

^c ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^d Department of Anesthesiology Private Hospital Antony of Paris   (France)

^e UNIVERSITY HOSPITAL OF SAINT ETIENNE   (France)

^f HÔPITAL ARNAUD DE VILLENEUVE   (France)

^g LILLE UNIVERSITY HOSPITAL   (France)

^h Institut Cochin   (France)

ⁱ UNIVERSITY HOSPITAL OF NICE   (France)

^j GENEVA UNIVERSITY HOSPITALS   (Switzerland)

more..

Author keywords

FVIIa activated; Hysterectomy; Postpartum hemorrhage; Treatment efficacy; Treatment outcome

Indexed keywords

APROTININ; ENOXAPARIN; FIBRINOGEN CONCENTRATE; FRESH FROZEN PLASMA; HEMOGLOBIN; OXYTOCIN; RECOMBINANT BLOOD CLOTTING FACTOR 7A; RECOMBINANT HUMAN BLOOD CLOTTING FACTOR 2A; SULPROSTONE; THROMBOCYTE CONCENTRATE; UNCLASSIFIED DRUG; BLOOD CLOTTING FACTOR 8; COAGULATING AGENT; F8 PROTEIN, HUMAN; PROSTAGLANDIN E2;

ADULT; ANTICOAGULANT THERAPY; ARTERY LIGATION; ARTICLE; ATTRIBUTABLE RISK; CESAREAN SECTION; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DEATH; DEEP VEIN THROMBOSIS; DISEASE SEVERITY; DRUG EFFICACY; ERYTHROCYTE CONCENTRATE; ERYTHROCYTE TRANSFUSION; FEMALE; FETUS DEATH; FIBRINOGEN BLOOD LEVEL; HEMOGLOBIN DETERMINATION; HEMOSTASIS; HUMAN; HYSTERECTOMY; INTRAUTERINE BALLOON; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MULTICENTER STUDY; OPEN STUDY; OUTCOME ASSESSMENT; OVARIAN VEIN THROMBOSIS; POSTPARTUM HEMORRHAGE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; RISK FACTOR; SINGLE DRUG DOSE; STANDARD; THROMBOCYTE TRANSFUSION; TREATMENT OUTCOME; UTERINE ARTERY EMBOLIZATION; VAGINAL DELIVERY; VEIN THROMBOSIS; ADVERSE EFFECTS; ANALOGS AND DERIVATIVES; CHEMICALLY INDUCED; CLINICAL TRIAL; COMPASSIONATE USE; DRUG ADMINISTRATION; FRANCE; HEMOSTATIC TECHNIQUE; INTRAVENOUS DRUG ADMINISTRATION; MORTALITY; PREGNANCY; SEVERITY OF ILLNESS INDEX; SWITZERLAND; TIME FACTOR; TREATMENT FAILURE;

ADULT; COAGULANTS; COMPASSIONATE USE TRIALS; DINOPROSTONE; DRUG ADMINISTRATION SCHEDULE; FACTOR VIII; FEMALE; FRANCE; HEMOSTATIC TECHNIQUES; HUMANS; HYSTERECTOMY; INFUSIONS, INTRAVENOUS; POSTPARTUM HEMORRHAGE; PREGNANCY; RISK FACTORS; SEVERITY OF ILLNESS INDEX; SWITZERLAND; TIME FACTORS; TREATMENT FAILURE; VENOUS THROMBOSIS;

EID: 84926107882     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/jth.12844     Document Type: Article

References (32)

1. Bonnar J. Massive obstetric hemorrhage. Baillieres Best Pract Res Clin Obstet Gynaecol 2000; 14: 118.
2. Oyelese Y, Ananth CV. Postpartum hemorrhage: epidemiology, risk factors, and causes. Clin Obstet Gynecol 2010; 53: 147-56.
3. Hogan MC, Foreman KJ, Naghavi M, Ahn SY, Wang M, Makela SM, Lopez AD, Lozano R, Murray CJ. Maternal mortality for 181 countries, 1980-2008: a systematic analysis of progress towards Millennium Development Goal 5. Lancet 2010; 375: 1609-23.
4. Abou Zahr C. Global burden of maternal death and disability. Br Med Bull 2003; 67: 1-11.
5. Waterstone M, Bewley S, Wolfe C. Incidence and predictors of severe obstetric morbidity: a case-control study. BMJ 2001; 322: 1089-93.
6. Roberts CL, Ford JB, Algert CS, Bell JC, Simpson JM, Morris JM. Trends in adverse maternal outcomes during childbirth: a population-based study of severe maternal morbidity. BMC Pregnancy Childbirth 2009; 9: 7.
7. McLintock C, James AH. Obstetric hemorrhage. J Thromb Haemost 2011; 9: 1441-51.
8. Wen SW, Huang L, Liston R, Heaman M, Baskett T, Rusen ID, Joseph KS, Kramer MS, Maternal Health Study Group, Canadian Perinatal Surveillance System. Severe maternal morbidity in Canada, 1991-2001. CMAJ 2005; 173: 759-64.
9. Zhang WH, Alexander S, Bouvier-Colle MH, Macfarlane A. Incidence of severe pre-eclampsia, postpartum hemorrhage and sepsis as a surrogate marker for severe maternal morbidity in a European population-based study: the MOMS-B survey. BJOG 2005; 112: 89-96.
10. Zwart J, Richters J, Öry F, de Vries J, Bloermenkamp K, van Roosmalen J. Severe maternal morbidity during pregnancy, delivery and puerperium in the Netherlands: a nationwide population-based study of 371 000 pregnancies. BJOG 2008; 115: 842-50.
11. Al-Zirqi I, Vangen S, Forsen L, Stray-Pedersen B. Prevalence and risk factors of severe obstetric hemorrhage. BJOG 2008; 115: 1265-72.
12. Knight M, Callaghan WM, Berg C, Alexander S, Bouvier-Colle MH, Ford JB, Joseph KS, Lewis G, Liston RM, Roberts CL, Oats J, Walker J. Trends in postpartum hemorrhage in high resource countries: a review and recommendations from the International Post-partum Hemorrhage Collaborative Group. BMC Pregnancy Childbirth 2009; 27: 55.
13. Devine PC. Obstetric hemorrhage. Semin Perinatol 2009; 33: 76-81.
14. Goffinet F, Mercier F, Teyssier V, Pierre F, Dreyfus M, Mignon A, Carbonne B, Levy G. Postpartum hemorrhage: recommendations for clinical practice by the CNGOF. Gynecol Obstet Fertil 2005; 33: 268-74.
15. Gülmezoglu AM, Forna F, Villar J, Hofmeyr GJ. Prostaglandins for prevention of postpartum hemorrhage. Cochrane Database Syst Rev 2001;(4):CD000494.
16. American Society of Anesthesiologists Task Force on Obstetric Anesthesia. Practice guidelines for obstetric anesthesia: an updated report by the American Society of Anesthesiologists Task Force on Obstetric Anesthesia. Anesthesiology 2007; 106: 843-63.
17. Franchini M, Franchi M, Bergamini V, Salvagno GL, Montagnana M, Lippi G. A critical review on the use of recombinant factor VIIa in life-threatening obstetric postpartum hemorrhage. Semin Thromb Hemost 2008; 34: 104-12.
18. Franchini M, Franchi M, Bergamini V, Montagnana M, Salvagno GL, Targher G, Lippi G. Guidelines for the use of recombinant activated factor VII in massive obstetric hemorrhage. Aust N Z J Obstet Gynaecol 2008; 48: 12-6.
19. Schulz KF, Altman DG, Moher D, for the CONSORT Group. Recombinant activated factor VII in obstetric hemorrhage: experiences from the Australian and New Zealand Haemostasis Registry. Anest Analg 2009; 6: 1908-15.
20. Franchini M, Franchi M, Bergamini V, Montagnana M, Salvagno GL, Targher G, Lippi G. The use of recombinant activated FVII in postpartum hemorrhage. Clin Obstet Gynecol 2010; 53: 219-27.
21. ®) in the management of severe postpartum hemorrhage: initial report of a multicenter case series in Japan. Int J Hematol 2012; 95: 57-63.
22. Schulz KF, Altman DG, Moher D, for the CONSORT Group. CONSORT 2010 statement. Updated guidelines for reporting parallel group randomised trials. Ann Intern Med 2010; 152: 726-32.
23. Moher D, Hopewell S, Schulz KF, Montori V, Gøtzsche PC, Devereaux PJ, Elbourne D, Egger M, Altman DG, for the CONSORT Group. CONSORT 2010 explanation and elaboration: updated guidelines for reporting parallel group randomised trial. BMJ 2010; 23: c869.
24. Jacobsen AF, Skjeldestad FE, Sandset PM. Ante and postnatal risk factors of venous thrombosis: a hospital-based case-control study. J Thromb Haemost 2008; 6: 905-12.
25. Kayem G, Kurinczuk JJ, Alfirevic Z, Spark P, Brocklehurst P, Knight M. Specific second-line therapies for postpartum hemorrhage: a national cohort study. BJOG 2011; 118: 856-64.
26. Benhamou D, Mignon A, Aya G, Brichant JF, Bonnin M, Chauleur C, Deruelle P, Ducloy AS, Edelman P, Rigouzzo A, Riu B. Prophylaxis of thromboembolic complications in obstetrics and gynaecology. Ann Fr Anesth Reanim 2005; 24: 911-20.
27. Chauleur C, Gris JC, Seffert P, Mismetti P. Latest developments on risk factors and prophylaxis of thromboembolic disease in obstetrics. Gynecol Obstet Fertil 2012; 40: 301-7.
28. Mercier FJ, van de Velde M. Major obstetric hemorrhage. Anesthesiol Clin 2008; 26: 53-66.
29. Mayer SA, Brun NC, Begtrup K, Recombinant Activated Factor VII Intracerebral Hemorrhage Trial Investigators. Recombinant activated factor VII for acute intracerebral hemorrhage. N Engl J Med 2005; 352: 777-85.
30. Mayer SA, Brun NC, Begtrup K, Broderick J, Davis S, Diringer MN, Skolnick BE, Steiner T. Efficacy and safety of recombinant activated factor VII for acute intracerebral hemorrhage. N Engl J Med 2008; 358: 2127-37.
31. Diringer MN, Skolnick BE, Mayer SA, Steiner T, Davis SM, Brun NC, Broderick JP. Risk of thromboembolic events in controlled trials of rFVIIa in spontaneous intracerebral hemorrhage. Stroke 2008; 39: 850-6.
32. Simpson E, Lin Y, Stanworth S, Birchall J, Doree C, Hyde C. Recombinant factor VIIa for the prevention and treatment of bleeding in patients without haemophilia. Cochrane Database Syst Rev 2012;(14):CD005011.